Novartis: seeks OK from EU for CAR-T therapy.
(CercleFinance.com) - Novartis has reached another regulatory milestone for CTL019, the world's first-ever FDA approved CAR-T therapy, by submitting a marketing authorisation for two indications in Europe.
The application deals with the treatment of children and young adults with relapsed or refractory B-cell acute lymphoblastic leukemia (ALL) and for adult patients with r/r diffuse large B-cell lymphoma (DLBCL) who are ineligible for autologous stem cell transplant (ASCT).
CTL019 - a novel immuno-cellular therapy that uses a patient's own T cells to fight cancer - has been approved by the US FDA for the treatment of young patients with leukemia in August, a first for this type of treatment.
This morning Novartis also published new long-term Cosentyx data for patients with ankylosing spondylitis, showing that almost 80% of patients treated have no radiographic progression of the spine at four years.
Copyright (c) 2017 CercleFinance.com. All rights reserved.
The application deals with the treatment of children and young adults with relapsed or refractory B-cell acute lymphoblastic leukemia (ALL) and for adult patients with r/r diffuse large B-cell lymphoma (DLBCL) who are ineligible for autologous stem cell transplant (ASCT).
CTL019 - a novel immuno-cellular therapy that uses a patient's own T cells to fight cancer - has been approved by the US FDA for the treatment of young patients with leukemia in August, a first for this type of treatment.
This morning Novartis also published new long-term Cosentyx data for patients with ankylosing spondylitis, showing that almost 80% of patients treated have no radiographic progression of the spine at four years.
Copyright (c) 2017 CercleFinance.com. All rights reserved.